Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
PRIMARY OBJECTIVES:
I. To obtain results from a high throughput drug sensitivity assay within 10 days, procure
drug within 14 days and initiate treatment within 21 days.
SECONDARY OBJECTIVES:
I. To achieve a response (cytoreduction or at least partial response) greater that than
expected for comparable refractory patient populations with other salvage regimens.
OUTLINE:
Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity
assay.
After completion of study treatment, patients are followed every 3 months for 2 years.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility defined as results from a high throughput drug sensitivity assay within 10 days, procure drug within 14 days and initiate treatment within 21 days
Up to 21 days
No
Pamela Becker
Principal Investigator
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
United States: Federal Government
8003
NCT01872819
June 2013
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle, Washington 98109 |